Drug intelligence / Profile preview

spirilloxanthin

Development stage: Preclinical
Modality: Small Molecules

Overview

Spirilloxanthin is a major bioactive natural compound identified in the flower extract of *Verbesina encelioides* (VFE). It has demonstrated neuroprotective benefits in scopolamine-induced memory impaired rat models resembling Alzheimer's disease. Studies suggest it improves learning and memory, reduces free radical production, and mitigates oxidative stress. In silico molecular docking studies indicate potential interactions with acetylcholinesterase, suggesting a mechanism of action involving acetylcholinesterase inhibition.

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on spirilloxanthin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spirilloxanthin.

Explore the full profile